These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28837162)

  • 1. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility.
    Catucci I; Osorio A; Arver B; Neidhardt G; Bogliolo M; Zanardi F; Riboni M; Minardi S; Pujol R; Azzollini J; Peissel B; Manoukian S; De Vecchi G; Casola S; Hauke J; Richters L; Rhiem K; Schmutzler RK; Wallander K; Törngren T; Borg Å; Radice P; Surrallés J; Hahnen E; Ehrencrona H; Kvist A; Benitez J; Peterlongo P
    Genet Med; 2018 Apr; 20(4):452-457. PubMed ID: 28837162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
    Keupp K; Hampp S; Hübbel A; Maringa M; Kostezka S; Rhiem K; Waha A; Wappenschmidt B; Pujol R; Surrallés J; Schmutzler RK; Wiesmüller L; Hahnen E
    Mol Genet Genomic Med; 2019 Sep; 7(9):e863. PubMed ID: 31347298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia.
    Bogliolo M; Bluteau D; Lespinasse J; Pujol R; Vasquez N; d'Enghien CD; Stoppa-Lyonnet D; Leblanc T; Soulier J; Surrallés J
    Genet Med; 2018 Apr; 20(4):458-463. PubMed ID: 28837157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
    García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
    Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics.
    Bogliolo M; Surrallés J
    Curr Opin Genet Dev; 2015 Aug; 33():32-40. PubMed ID: 26254775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.
    Sawyer SL; Tian L; Kähkönen M; Schwartzentruber J; Kircher M; ; ; Majewski J; Dyment DA; Innes AM; Boycott KM; Moreau LA; Moilanen JS; Greenberg RA
    Cancer Discov; 2015 Feb; 5(2):135-42. PubMed ID: 25472942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).
    McReynolds LJ; Biswas K; Giri N; Sharan SK; Alter BP
    Cancer Genet; 2021 Nov; 258-259():101-109. PubMed ID: 34687993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
    Reid S; Schindler D; Hanenberg H; Barker K; Hanks S; Kalb R; Neveling K; Kelly P; Seal S; Freund M; Wurm M; Batish SD; Lach FP; Yetgin S; Neitzel H; Ariffin H; Tischkowitz M; Mathew CG; Auerbach AD; Rahman N
    Nat Genet; 2007 Feb; 39(2):162-4. PubMed ID: 17200671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.
    Virts EL; Jankowska A; Mackay C; Glaas MF; Wiek C; Kelich SL; Lottmann N; Kennedy FM; Marchal C; Lehnert E; Scharf RE; Dufour C; Lanciotti M; Farruggia P; Santoro A; Savasan S; Scheckenbach K; Schipper J; Wagenmann M; Lewis T; Leffak M; Farlow JL; Foroud TM; Honisch E; Niederacher D; Chakraborty SC; Vance GH; Pruss D; Timms KM; Lanchbury JS; Alpi AF; Hanenberg H
    Hum Mol Genet; 2015 Sep; 24(18):5093-108. PubMed ID: 26085575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neglected members of the family: non-BRCA mutations in the Fanconi anemia/BRCA pathway and reproduction.
    Vanni VS; Campo G; Cioffi R; Papaleo E; Salonia A; Viganò P; Lambertini M; Candiani M; Meirow D; Orvieto R
    Hum Reprod Update; 2022 Feb; 28(2):296-311. PubMed ID: 35043201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fanconi-like anemia related to a FANCM mutation.
    Encarnación JA; Cerezuela P; Español I; García MR; Manso C; De la Fuente I; Garrigós N; Viney A; Minguillon J; Surrallés J
    Eur J Med Genet; 2022 Jan; 65(1):104399. PubMed ID: 34793962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
    Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fanconi anemia: causes and consequences of genetic instability.
    Kalb R; Neveling K; Nanda I; Schindler D; Hoehn H
    Genome Dyn; 2006; 1():218-242. PubMed ID: 18724063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
    Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
    Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
    Kiiski JI; Pelttari LM; Khan S; Freysteinsdottir ES; Reynisdottir I; Hart SN; Shimelis H; Vilske S; Kallioniemi A; Schleutker J; Leminen A; Bützow R; Blomqvist C; Barkardottir RB; Couch FJ; Aittomäki K; Nevanlinna H
    Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15172-7. PubMed ID: 25288723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients.
    Freire BL; Homma TK; Funari MFA; Lerario AM; Leal AM; Velloso EDRP; Malaquias AC; Jorge AAL
    Eur J Med Genet; 2018 Mar; 61(3):130-133. PubMed ID: 29133208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
    García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
    Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel splice site mutation in the noncoding region of BRCA2: implications for Fanconi anemia and familial breast cancer diagnostics.
    Bakker JL; Thirthagiri E; van Mil SE; Adank MA; Ikeda H; Verheul HM; Meijers-Heijboer H; de Winter JP; Sharan SK; Waisfisz Q
    Hum Mutat; 2014 Apr; 35(4):442-6. PubMed ID: 24395671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.